AstraZeneca shares rise as COVID-19vaccine trials resume

AstraZeneca shares rise as COVID-19vaccine trials resume

In the U.S., regulators are more hesitant to resume the trial, with the government-funded National Institutes of Health having now launched an investigation of its own, Kaiser Health News reported Monday.

Phase II trials are created to test which dose and schedule of a vaccine generates the most antibodies while Phase III tests the vaccine's efficacy.

Pfizer Inc says participants have shown mild to moderate side effects from either its experiment coronavirus vaccine or a placebo with the fatigue being the most common sign.

After the second dose, 36 percent of the age 18-to-64 group and 27 percent of the age 65-to-84 group reported fatigue.

'[Researchers] would notify us if they had any safety concerns and have not done that to date, ' Dr Kathrin Jansen, Pfizer's head of vaccine research, said on the call.

Johnson & Johnson's Belgian Janssen unit began phase two trials of its COVID-19 vaccine on 190 people in Spain on Monday with those tests due to conclude on September 22.

Ontario premier confirms new measures are coming for COVID-19 hotspots
The OHA echoed the same sentiment, saying Ontario's economy may be forced to shut down again if case numbers continue to rise. The majority of cases are from three regions - Peel, Toronto, and Ottawa and the five-day rolling average is 249 new cases.

Company CEO Albert Bourla has said it is "likely" the United States will get a coronavirus vaccine treatment to the public before the end of the year.

Novavax Inc last month separately said SK Bioscience, a unit of SK Chemicals, would manufacture a component of the USA drug developer's experimental coronavirus vaccine in a bid to boost its supply.

'What we are doing in terms of releasing data is very unusual, ' CEO Albert Bourla said, according to Bloomberg News.

Bourla told the media that the company releasing data is "very unusual" but called it a "must" due to ongoing discussions with the United States government and regulators. AstraZeneca announced last Saturday that it had resumed trials in Britain after regulators completed their review of a serious side effect in one trial participant there. The name of the vaccine candidate is Covishield. That is expected to trigger in turn an immune response so the body can fight off any future COVID-19 infection.

Volunteers given either the low or medium dose generated not just antibodies against the virus but specifically neutralizing antibodies, meaning they stop the virus from infecting human cells.

The world has pinned its hopes of countering coronavirus on the development of vaccines, with governments planning for their availability at the end of this year and the beginning of next.

Related Articles